In 2018, Alnylam seems poised to deliver its first big breakthrough. John Maraganore, CEO, sat down with LSL Chief Editor, Rob Wright, to share his perspectives on Alnylam’s upcoming year — including the good, the bad, and everything in-between.
Clay Siegall, Ph.D., president, CEO, and chairman of Seattle Genetics, gives an exclusive interview about his company’s potential blockbuster, how they got to this point, and what’s next.
Vinita Kumar, VP of quality at Versartis, talks about how her philosophy on CMO collaboration has been field-tested. “Never does that importance of real collaboration reveal itself more than in hard times for your program when you need it most,” she says.
With TEVA Pharmaceuticals out of the picture, Mesoblast had to figure out how to survive. Due to hard work, Mesoblast found a way to save their company and here is how they did it. “The termination left us in a hole. We had to gather our thoughts, allocate resources, and prove that the technology worked.”
“A partnering deal with a bigger pharma company would certainly help us through [the Phase 3] process,” explains Jeff Davidson, CEO of Keystone Nano, a company that develops nanoparticles that target solid tumors by going after cancer cells and leaving the normal cells intact.
According to Noubar Afeyan, founder and CEO of Flagship Pioneering, his company shouldn’t be pigeonholed as a VC firm. ““From day one, our intent was to innovate and create new companies.”
An inside look into how this fledgling biopharma has raised over $150 million and enlisted two high-profile CEOs from one of the hottest VC firms around, all in less than two years.
Former Pfizer exec and current partner at VC firm Polaris Partners Amy Schulman talks about what it takes to lead a pharma startup.
As CEO of Ensysce Biosciences, a semi-virtual company with three employees, Lynn Kirkpatrick, Ph.D., knows all about the funding struggles of a small company.
Casey Lynch has long had the gut feeling there was more to the cause of Alzheimer’s than beta amyloid and tau proteins. Turns out, she was right.
A look at the 26-year career of Pat Andrews, CEO of Boston Biomedical, who went from Big Pharma to small biotech.
The industry veteran talks about leaving Novartis to take care of her sister for a year and how that prepared her for her new job at Lilly.
When Joseph Papa took over Valeant Pharmaceuticals in May 2016, the company was in turmoil. We catch up with Papa and see how he’s coming with what he calls “the turnaround opportunity of a lifetime.”
Recounting what an executive did while on sabbatical wouldn’t normally fit into our editorial model. That is, unless that executive is Richard Bagger, J.D., EVP of corporate affairs and market access for Celgene.
Michael Bonney, CEO of Kaleido Biosciences, discusses some of the challenges faced — and how to overcome those — when building a diverse leadership team.
John Maraganore, CEO of Alnylam Pharmaceuticals and current chair for BIO, shares thoughts on CROs, open science, and his company’s future.
The CEO and founder of Seattle Genetics, Clay Siegall, discusses one of the company’s new technologies, sugar-engineered antibodies (SEAs).
Readers provide feedback and suggestions around how the biopharmaceutical industry could help the homeless during the annual J.P. Morgan Healthcare Conference in San Francisco.
The Conference Forum’s 2018 R&D Leadership Summit employs the Chatham House Rule, which limits what information can be revealed from the event's proceedings. As one of the only members of the media in the room, Chief Editor Rob Wright shares what he can from this year's event, which had the theme “Growth: Where Will It Come From?”
